Clinical Policy Title: Botanical marijuana for medical use
|
|
- Gwenda Johnston
- 5 years ago
- Views:
Transcription
1 Clinical Policy Title: Botanical marijuana for medical use Clinical Policy Number: Effective Date: January 1, 2015 Initial Review Date: August 20, 2014 Most Recent Review Date: October 19, 2017 Next Review Date: October 2018 Policy contains: Medical marijuana. Cannabis. Tetrahydrocannabinol. Hydrocannabinol. Related policies: None. ABOUT THIS POLICY: Select Health of South Carolina has developed clinical policies to assist with making coverage determinations. Select Health of South Carolina s clinical policies are based on guidelines from established industry sources, such as the Centers for Medicare & Medicaid Services (CMS), state regulatory agencies, the American Medical Association (AMA), medical specialty professional societies, and peerreviewed professional literature. These clinical policies along with other sources, such as plan benefits and state and federal laws and regulatory requirements, including any state- or plan-specific definition of medically necessary, and the specific facts of the particular situation are considered by Select Health of South Carolina when making coverage determinations. In the event of conflict between this clinical policy and plan benefits and/or state or federal laws and/or regulatory requirements, the plan benefits and/or state and federal laws and/or regulatory requirements shall control. Select Health of South Carolina s clinical policies are for informational purposes only and not intended as medical advice or to direct treatment. Physicians and other health care providers are solely responsible for the treatment decisions for their patients. Select Health of South Carolina s clinical policies are reflective of evidence-based medicine at the time of review. As medical science evolves, Select Health of South Carolina will update its clinical policies as necessary. Select Health of South Carolina s clinical policies are not guarantees of payment. Coverage policy Select Health of South Carolina considers the use of botanical marijuana to be investigational and, therefore, not medically necessary (National Academies of Sciences, Engineering, and Medicine [NASEM], 2017; U.S. Food and Drug Administration [FDA], 2017 and 2016). For the purpose of this policy, the term marijuana refers to the dried leaves and flowers of marijuana, and any mixture or preparation thereof, and does not include FDA-approved drugs that may contain active ingredients that are present in marijuana (e.g., dronabinol or nabilone). This policy applies to any method of absorption, including but not limited to smoking, vaporizing, nasal or oral sprays, and oral ingestion. Limitations: None. Alternative covered services: 1
2 FDA-approved drugs represented in evidence-based practice standards. Background Cannabis, also known as marijuana, is the dried leaves and flowering tops of the cannabis plant, most commonly, cannabis sativa. Cannabis produces terpenophenolic compounds called cannabinoids, which activate specific receptors found throughout the body, particularly in the central nervous system and the immune system, causing pharmacologic effects in the body. Tetrahydrocannabinol (THC) is the main cannabinoid found in cannabis and largely responsible for its psychoactive effects (National Cancer Institute [NCI], 2017). Cannabis may be taken by mouth or inhaled. When taken by mouth (in baked products or as an herbal tea), THC is processed by the liver, making an additional psychoactive chemical. When cannabis is smoked and inhaled, cannabinoids quickly enter the bloodstream. The additional psychoactive chemical is produced in smaller amounts than when taken by mouth (NCI, 2017). Medical marijuana refers to the use of cannabis and its constituents as a physician-recommended form of medicine or herbal therapy. Marijuana or marijuana-derived products are being used for a number of medical conditions, including AIDS wasting, epilepsy, neuropathic pain, treatment of spasticity associated with multiple sclerosis (MS), and cancer- and chemotherapy-induced nausea and vomiting (CINV) (FDA, 2017). The risks and benefits of its medicinal use are unclear (NCI, 2017). The most rigorous studies have reported adverse events associated with its recreational use, but extrapolating results of recreational cannabis use cannot be expected to occur with medical marijuana use. The amounts used, the existence of comorbidities, and the methods of drug delivery may differ between the two populations. Therefore, there is a strong scientific rationale for evaluating medical marijuana separately (Wang, 2008). Regulation: In the United States, marijuana is a Schedule I controlled substance requiring special licensing for its use; it has no recognized medical use, carries a high risk of dependency, and is illegal to use and distribute (21 U.S.C. 801). The FDA is responsible for the approval and marketing of drugs for medical use, including controlled substances (FDA, 2017). Several states have either passed laws that remove state restrictions on the medical use of marijuana and its derivatives, or are considering doing so. To date, the FDA has not approved a marketing application for a drug product containing or derived from botanical marijuana, and has not found any such product to be safe and effective for any indication (FDA, 2017). The FDA has approved two drugs that have synthetic THC as an active ingredient. Dronabinol, marketed as Marinol (AbbVie Inc., North Chicago, Illinois) and Syndros (Insys Therapeutics, Inc., Chandler, Arizona), is approved for anorexia associated with weight loss in patients with AIDS and for nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to 2
3 conventional antiemetic treatments. Nabilone is marketed as Cesamet (Valeant Pharmaceuticals, Aliso Viejo, California), which has a chemical structure similar to THC and is approved for CINV in patients who have failed to respond adequately to conventional antiemetic treatments. Dronabinol and nabilone are administered orally in capsule form (FDA, 2017). In April 2014, the FDA granted Fast-Track designation to the investigational drug product Sativex (GW Pharmaceuticals, United Kingdom) (FDA, 2016). Sativex is composed primarily of cannabidiol (CBD) and THC; it is administered as a metered dose oromucosal spray for the treatment of pain in patients with advanced cancer, who experience inadequate analgesia during optimized chronic opioid therapy. Sativex is currently in Phase III clinical trials for this indication. On June 6, 2014, the FDA granted Fast-Track designation to Epidiolex (GW Pharmaceuticals, United Kingdom), for treatment of Dravet syndrome, a rare and catastrophic treatment-resistant form of childhood epilepsy. Fast-Track designation provides for more frequent meetings and communications with the FDA to discuss the drug s development plan and ensures collection of appropriate data needed to support drug approval, including the design of the proposed clinical trials and use of biomarkers (FDA, 2016). Medical uses of smoked, inhaled, ingested, or sprayed botanical marijuana are the focus of this clinical policy. This policy excludes Marinol, Cesamet, Sativex, or Epidiolex for clinical use, and marijuana for recreational use. Searches Select Health of South Carolina searched PubMed and the databases of: UK National Health Services Centre for Reviews and Dissemination. Agency for Healthcare Research and Quality s National Guideline Clearinghouse and other evidence-based practice centers. The Centers for Medicare & Medicaid Services (CMS). We conducted searches on August 30, Search terms were: "Cannabis"(MeSH) and "Medical Marijuana"(MeSH). We included: Systematic reviews, which pool results from multiple studies to achieve larger sample sizes and greater precision of effect estimation than in smaller primary studies. Systematic reviews use predetermined transparent methods to minimize bias, effectively treating the review as a scientific endeavor, and are thus rated highest in evidence-grading hierarchies. Guidelines based on systematic reviews. 3
4 Economic analyses, such as cost-effectiveness, and benefit or utility studies (but not simple cost studies), reporting both costs and outcomes sometimes referred to as efficiency studies which also rank near the top of evidence hierarchies. Findings We identified 10 systematic reviews for this policy. The systematic reviews examined the safety and effectiveness of cannabis and cannabinoids for several medical uses. These uses include wasting and cachexia in patients with HIV/AIDS, pain and spasticity in patients with amyotrophic lateral sclerosis (ALS)/motor neuron disease, antiemesis for CINV, ataxia associated with MS, dyskinesia in Parkinson s disease, intraocular pressure in glaucoma, and symptoms of asthma. We found no economic analyses or evidence-based guidelines for this policy. The evidence is insufficient to support the use of botanical (smoked) marijuana for medical use. Most of the available evidence from randomized controlled trials (RCTs) with placebo controls was intended to assess the safety and efficacy of oral delta-9-thc in patients who had failed conventional therapies. Relatively few RCTs have evaluated the safety and efficacy of smoked marijuana for medical use. All of the studies involved small numbers of patients and were of short duration, lasting from several days to weeks, depending on the condition being treated. Studies carried out in the 1970s and 1980s compared medical marijuana to outdated standards of care and lacked measurement of benefits and harms associated with long-term inhaled marijuana use. The paucity and poor quality of the evidence make it difficult to compare botanical marijuana with current pharmaceuticals that have received regulatory approval under more rigorous experimental conditions. Marijuana contains a variable mixture of poorly defined biologically active compounds and the level of THC fluctuates significantly between samples, making it impossible to quantify by inspection. The concept of a predictable, quantifiable "dose" is a fundamental principle of medical therapy, but few (if any) of the prescribing criteria of medical pharmacology can be met in the case of smoked or ingested botanical marijuana (Fisher, 2002). Our searches and a report by the Canadian Agency for Drugs and Technologies in Health (CADTH) found no evidence-based guidelines supporting the use of medical marijuana for specific medical conditions (CADTH, 2013). Practitioners recognized that marijuana might have treatment potential for certain medical symptoms. However, they are not uniform in their support for, or opposition to, medical marijuana. Several major medical organizations in the United States have not endorsed the use of medical marijuana, but most have called for expedited clinical research to discern its safety, dosage, and effectiveness, particularly of cannabinoids rather than smoked marijuana (American Academy of Pediatrics, 2015; American Academy of Child and Adolescent Psychiatry, 2012; American College of Physicians, 2008). Policy updates: 4
5 In 2015, we identified one new systematic review for this update (Koppel, 2014). The results of the review do not change the previous conclusions. Therefore, no changes to the policy are warranted. In 2016, we identified two new evidence-based guidelines, four systematic review and meta-analyses, and one large epidemiologic study for this policy. Guidelines by the American Congress of Obstetricians and Gynecologists (ACOG) and the American Academy of Neurology (AAN) cite the limited evidence supporting the safety and efficacy of medical cannabis use in pregnant women and persons with MS, respectively (ACOG, 2015; Yadav, 2014). Both guidelines highlight concerns for known adverse effects and knowledge gaps in standardized administration of cannabis, long-term effects, and interactions with other drug treatments. Results of three new systematic reviews and meta-analyses suggest botanical cannabis offers short-term relief of chronic neuropathic pain with non-serious side effects when used in conjunction with traditional analgesics, but comparisons to treatment alternatives are lacking, as are long-term safety and effectiveness data (Andreae, 2015; Deshpande, 2015; Whiting, 2015). In addition, Whiting (2015) found low-to-moderate quality evidence that botanical cannabis improved CINV, weight gain in HIV infection, sleep disorders, and Tourette syndrome, but also increased the risk of adverse effects, including some serious ones such as psychosis. Gurney (2015) found low-quality evidence supporting an association between cannabis use and increased risk of developing non-seminoma testicular germ cell cancer, particularly among current users, at least weekly users and chronic users (> 10 years), compared to those who never used cannabis. Finally, a large epidemiologic survey of 34,653 adults aged 18 years in the United States found cannabis use was significantly associated with an increased risk for several substance use disorders (SUDs) (Blanco, 2016). Based on the new evidence, the benefits of botanical cannabis for medical use do not outweigh the risks of adverse events for any indication. According to the FDA, additional research of its safety and effectiveness should be registered by the Drug Enforcement Administration and conducted under an FDA investigational new drug application and research protocol using medical grade cannabis supplied by the National Institute on Drug Abuse (FDA, 2016). In 2017, we added one evidence-based guideline by the American Society of Clinical Oncology (ASCO) that addressed medical marijuana use for treating chronic cancer pain in adults (Paice, 2016), and one comprehensive systematic review of the health effects of cannabis and cannabinoid use for multiple indications (National Academies of Sciences, Engineering, and Medicine [NASEM], 2017). The NASEM review included the systematic reviews identified previously in this policy. While fairly high quality evidence from controlled studies supports the effectiveness of medical cannabis for treating chronic pain of various etiologies, most of the studies were carried out in other countries (NASEM, 2017). Very little is known about the efficacy, dose, routes of administration, or side effects of commonly used and commercially available cannabis products in the United States. Moreover, many of the cannabis products sold in state-regulated markets do not resemble the products available for research at the federal level in the United States. There is insufficient evidence upon which to base 5
6 conclusions about therapeutic risks and benefits for other medical indications (NASEM, 2017). The new information does not change previous policy findings, and no policy changes are warranted. Summary of clinical evidence: Citation NASEM (2017) Health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research (Results for smoking or inhaled cannabis only) Blanco (2016) Cannabis use and risk of psychiatric disorders Paice (2016) for ASCO Content, Methods, Recommendations Systematic review of selected fair-to-good quality systematic reviews (published since 2011) and subsequent high-quality primary research for multiple medical conditions. Evidence of treatment effectiveness of cannabis: - Sufficient evidence for pain, but very little is known about the efficacy, dose, routes of administration, or side effects of commonly used and commercially available cannabis products in the United States. - Insufficient for CINV. - Limited for increasing appetite and decreasing weight loss associated with HIV/AIDS. - No or insufficient evidence for all other indications. Limited evidence of no association between smoking cannabis and risk for certain cancers (i.e., lung, head and neck) in adults. Limited evidence of an association between cannabis smoking and non-seminomatype testicular germ cell tumors (current, frequent, or chronic cannabis smoking). No or insufficient evidence of association between cannabis use and incidence of esophageal cancer. A nationally representative sample of 34,653 U.S. adults aged 18 years interviewed three years apart in the National Epidemiologic Survey on Alcohol and Related Conditions (wave 1, ; wave 2, ) using multiple regression analysis and propensity score matching used to estimate association between cannabis use at wave 1 and incidence and prevalence of Alcohol Use Disorder and Associated Disabilities Interview Schedule-DSM-IV psychiatric disorders at wave 2. Within the general population, cannabis use in wave 1 was significantly associated with an increased risk for several SUDs in wave 2 (odds ratio [OR], 95% confidence interval [CI]): - Any SUD: 6.2 ( ). - Any alcohol use disorder: 2.7 ( ). - Any cannabis use disorder: 9.5 ( ). - Any other drug use disorder: 2.6 ( ). - Nicotine dependence: 1.7 ( ). - But not mood disorder (1.1, ) or anxiety disorder (0.9, ). Guideline: management of chronic pain in survivors of adult cancer Clinicians may follow specific state regulations that allow access to medical cannabis or cannabinoids for patients with chronic pain after a consideration of the potential benefits and risks of the available formulations. (Evidence-based; benefits outweigh harms; evidence quality: intermediate; strength of recommendation: moderate). 6
7 Citation ACOG Committee Opinion (2015) Guideline for marijuana use during pregnancy and lactation Andreae (2015) Inhaled cannabis for chronic neuropathic pain Deshpande (2015) Medical marijuana for chronic non-cancer pain (CNCP) Gurney (2015) Content, Methods, Recommendations There are no FDA-approved indications, contraindications, safety precautions, or recommendations regarding its use during pregnancy and lactation. There are no standardized formulations, dosages, or delivery systems. Obstetrician gynecologists should be discouraged from prescribing or suggesting the use of marijuana for medicinal purposes during preconception, pregnancy, and lactation. Pregnant women or women contemplating pregnancy should be encouraged to discontinue use of medical marijuana in favor of alternative therapies with better pregnancy-specific safety data. High-quality studies regarding the effects of marijuana and other cannabis products on pregnancy and lactation are needed. A meta-analysis of individual patient data from five RCTs (178 participants with chronic neuropathic pain with 405 observed responses) following patients for days to weeks. Inhaled cannabis may provide short-term pain relief for one in five to six patients. Results limited by small number of studies and participants, short follow up, shortcomings in allocation concealment, and considerable attrition. Pragmatic trials are needed to evaluate the long-term benefits and risks. Systematic review of six RCTs (226 total patients) of medical marijuana in CNCP with other concomitant analgesics including opioids and anticonvulsants. Overall quality: moderate. All limited by lack of masking, short duration (maximum of 5 days), variability in dosing and strength of delta-9-thc, and lack of functional outcomes. Three of six trials reported clinically meaningful pain reduction using low-dose (< 34 mg/d) medical marijuana in refractory neuropathic pain of moderate severity in conjunction with traditional analgesics with non-serious side effects. Functional assessment and quality of life domains not reported. Comparisons to other treatment alternatives are lacking, and long-term psychoactive and neurocognitive effects remain unknown. Evidence does not support generalizing the use of medical marijuana to all CNCP conditions. Cannabis exposure and risk of testicular cancer Systematic review and meta-analysis of three case-control studies (719 total cases, 1,419 controls) conducted in the United States in the 1990s. Overall quality: low with a high risk of bias. Limited by low and differential response rates between groups, non-validated self-reported use, and lack of blinding. Current use of cannabis (pooled summary OR 1.62, 95% CI ), using cannabis at least weekly (1.92, ) and long duration (> 10 years) of cannabis use (1.50, ) are all associated with increased risk of developing a nonseminoma testicular germ cell tumor compared to those who never used cannabis. 7
8 Citation Whiting (2015) Cannabinoids for medical use: CINV, appetite stimulation in HIV/AIDS, chronic pain, spasticity due to multiple sclerosis or paraplegia, depression, anxiety disorder, sleep disorder, psychosis, glaucoma, or Tourette syndrome Koppel (2014) MS, epilepsy, and movement disorders. Yadav (2014) for the AAN Evidence-based guideline: complementary and alternative medicine in MS Lutge (2013) Content, Methods, Recommendations Evidence of a relationship between cannabis use and the development of seminoma tumors was inconclusive. Systematic review and meta-analysis of 79 RCTs (6,462 total participants). Overall quality: low to moderate. Only four judged at low risk of bias. Mostly placebocontrolled. Most trials showed non-statistically significant improvement in symptoms. Moderate-quality evidence supports cannabinoid use for treatment of chronic pain and spasticity. Low-quality evidence suggests cannabinoid use improved CINV, weight gain in HIV infection, sleep disorders, and Tourette syndrome. Cannabinoids were associated with an increased risk of short-term adverse events (AE), including serious AEs. Common AEs included dizziness, dry mouth, nausea, fatigue, somnolence, euphoria, vomiting, disorientation, drowsiness, confusion, loss of balance, and hallucination. Systematic review of 34 studies (eight RCTs) (1948 November 2013) including two controlled studies of smoked marijuana. For spasticity, central pain or painful spasms in MS or seizure disorders, smoked marijuana is of unclear efficacy. Cognitive impairment is a significant adverse effect with smoked marijuana use. Comparative effectiveness to other drugs needs to be studied. Guideline included two non-rcts of inhaled cannabis use (57 total patients with mixed types of MS). Conflicting findings with respect to short-term reductions in spasticity, pain, measures of posture and balance and cognitive performance. Cannabinoids may cause adverse effects. Clinicians should exercise caution regarding standardized vs. non-standardized cannabis extracts and overall quality control/non-regulation. Interaction with MS disease-modifying therapies is unknown. Insufficient evidence to recommend for or against cannabis use. Cochrane review HIV/AIDS Seven RCTs (eight publications) of effects of cannabis (in its natural or artificially produced form) either smoked or ingested, on morbidity or mortality of patients infected with HIV. Overall quality: low. Short duration (21 days to 84 days); small numbers; allocation concealment variable but only dronabinol was expected to be more easily blinded; variable outcomes measured for change in weight, body fat, appetite, caloric intake, nausea and vomiting, performance and mood. Insufficient evidence for the efficacy and safety of cannabis and cannabinoids in persons with HIV/AIDS. Long-term data showing a sustained effect on AIDS-related 8
9 Citation Content, Methods, Recommendations morbidity, mortality and safety in patients on effective antiretroviral therapy, not available. References Professional society guidelines/other: ACOG Committee opinion No. 637: marijuana use during pregnancy and lactation. Obstet Gynecol. 2015; 126(1): American Academy of Pediatrics. The Impact of Marijuana Policies on Youth: Clinical, Research, and Legal Update. Pediatrics. 2015; 135(3): 584. DOI: /peds.digest1353. Medical marijuana policy statement. American Academy of Child and Adolescent Psychiatry website. spx. Accessed August 30, Rapid response report: reference list. The use of medical marijuana: guidelines and recommendations. 15 January Canadian Agency for Drugs and Technologies in Health (CADTH) website. Accessed August 30, Supporting research into the therapeutic role of marijuana. A position paper of the American College of Physicians. American College of Physicians website. uana.pdf. Accessed August 30, Yadav V, Bever C, Jr., Bowen J, et al. Summary of evidence-based guideline: complementary and alternative medicine in multiple sclerosis: report of the guideline development subcommittee of the American Academy of Neurology. Neurology. 2014; 82(12): Peer-reviewed references: 21 U.S.C Controlled Substances Act. Andreae MH, Carter GM, Shaparin N, et al. Inhaled Cannabis for Chronic Neuropathic Pain: A Metaanalysis of Individual Patient Data. J Pain. 2015; 16(12): Blanco C, Hasin DS, Wall MM, et al. Cannabis use and risk of psychiatric disorders: prospective evidence from a us national longitudinal study. JAMA Psychiatry. 2016; 73(4):
10 Brettschneider J, Kurent J, Ludolph A. Drug Therapy for Pain in Amyotrophic Lateral Sclerosis or Motor Neuron Disease. Cochrane Database Syst Rev. 2013(6): CD Cannabis and Cannabinoids (PDQ ). Overview. Updated April 7, National Cancer Institute website. Accessed September 7, Deshpande A, Mailis-Gagnon A, Zoheiry N, Lakha SF. Efficacy and adverse effects of medical marijuana for chronic noncancer pain: Systematic review of randomized controlled trials. Can Fam Physician. 2015; 61(8): e372 e381. FDA. News & Events. FDA and Marijuana: Questions and Answers. Page last updated August 15, FDA website. Accessed August 30, FDA. News & Events. Researching the Potential Medical Benefits and Risks of Marijuana. July 13, FDA website. Accessed August 30, Fisher B, Johnston D, Leake P for the Medical Services Workers' Compensation Board Alberta. Marijuana for medicinal purposes: An evidence-based assessment. June, Workers' Compensation Board of British Columbia website: Accessed August 30, Gurney J, Shaw C, Stanley J, Signal V, Sarfati D. Cannabis exposure and risk of testicular cancer: a systematic review and meta-analysis. BMC Cancer. 2015; 15: 897. Koppel BS, Brust JC, Fife T, et al. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014; 82(17): Lutge EE, Gray A, Siegfried N. The medical use of cannabis for reducing morbidity and mortality in patients with HIV/AIDS. Cochrane Database Syst Rev. 2013; 4: CD National Academies of Sciences, Engineering, and Medicine. The health effects of cannabis and cannabinoids: The current state of evidence and recommendations for research. Washington, DC: The National Academies Press; DOI: / Wang T, Collet JP, Shapiro S, Ware MA. Adverse Effects of Medical Cannabinoids: A Systematic Review. CMAJ: Canadian Medical Association Journal. 2008; 178(13):
11 Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: A systematic review and metaanalysis. Jama. 2015; 313(24): CMS National Coverage Determinations (NCDs): No NCDs identified as of the writing of this policy. Local Coverage Determinations (LCDs): No LCDs identified as of the writing of this policy. Commonly submitted codes Below are the most commonly submitted codes for the service(s)/item(s) subject to this policy. This is not an exhaustive list of codes. Providers are expected to consult the appropriate coding manuals and bill accordingly. CPT Code Description Comment No codes ICD-10 Code Description Comment No codes HCPCS Level ll Code No codes Description Comment 11
Clinical Policy Title: Botanical marijuana for medical use
Clinical Policy Title: Botanical marijuana for medical use Clinical Policy Number: CCP.1132 Effective Date: January 1, 2015 Initial Review Date: August 20, 2014 Most Recent Review Date: October 2, 2018
More informationClinical Policy Title: Botanical marijuana for medical use
Clinical Policy Title: Botanical marijuana for medical use Clinical Policy Number: 00.02.10 Effective Date: January 1, 2015 Initial Review Date: August 20, 2014 Most Recent Review Date: October 13, 2015
More informationMarijuana and Adolescents: Truth and Consequences. Disclosure Statement OBJECTIVES. Secondary Objectives. State of Marijuana in US
Marijuana and Adolescents: Truth and Consequences Clinical Advances in Pediatrics Symposium Children s Mercy Park September 28, 2017 Disclosure Statement I have no actual or potential conflict of interest
More informationMedicinal cannabinoids where does it fit in Palliative Care? Janet Hardy Phillip Good Georgie Cupples Matthew Spitzer
Medicinal cannabinoids where does it fit in Palliative Care? Janet Hardy Phillip Good Georgie Cupples Matthew Spitzer Medicinal cannabis Substantial public interest Legalised by the Qld Government Guidance
More informationUse of Cannabinoids in Medical Practice
Use of Cannabinoids in Medical Practice Annual Scientific Assembly Family Medicine Review 2016 Murray Opdahl BSPE, MD, CCFP Objectives Briefly present: An overview of available cannabinoids Concerns voiced
More informationA summary of reviews of evidence on the efficacy and safety of medical use of cannabis and cannabinoids
A summary of reviews of evidence on the efficacy and safety of medical use of cannabis and cannabinoids Background paper commissioned by the EMCDDA for the report Medical use of cannabis and cannabinoids:
More informationMedical Marijuana Consent Form
Medical Marijuana Consent Form A qualified physician may not delegate the responsibility of obtaining written informed consent to another person. The qualified patient or the patient s parent or legal
More informationA look at Marijuana in 2014
A look at Marijuana in 2014 Paul Snyder MA., LADC Overview and Objectives Discuss the mental and physical effects of marijuana use Describe the criteria for Cannabis use disorder according to the DSM 5
More informationMedical Cannabis MATT WEBSTER DO, MS
Medical Cannabis MATT WEBSTER DO, MS Cannabis Sativa One of the oldest used drugs and medicinal remedies Most commonly abused illicit drug in the US There has been increasing access for medicinal MJ use
More informationAct 16 and Medical Cannabis in Pennsylvania
Act 16 and Medical Cannabis in Pennsylvania Charles V. Pollack, Jr., MA, MD, FACEP, FAAEM, FAHA, FESC, FCPP Associate Provost and Professor of Emergency Medicine Director, Institute of Emerging Health
More informationThe Shifting Federal Regulation of Cannabis Products
The Durham Bar 2019 CLE Program The Shifting Federal Regulation of Cannabis Products Erica M. Jackson, FDA Partner K&L Gates February 6, 2019 Copyright 2018 by K&L Gates LLP. All rights reserved. OVERVIEW
More informationAcknowledgements: What it is What it s not. Cannabis Evidence Series. Evidence-informed decision-making
Cannabis Evidence Series What it is What it s not Acknowledgements: The evidence presented is from the Cannabis evidence series authored by the HTA unit at the University of Calgary and from Rapid response
More informationConsumer Information Cannabis (Marihuana, marijuana)
Consumer Information Cannabis (Marihuana, marijuana) The courts in Canada have ruled that the federal government must provide reasonable access to a legal source of marijuana for medical purposes. The
More informationThe Evidence. Alex Crawley, BSP, ACPR RxFiles Academic Detailing Program
The Evidence Alex Crawley, BSP, ACPR RxFiles Academic Detailing Program Disclosure I have no relationships with commercial entities I have no real or perceived conflicts of interest I am employed by the
More informationJames McCormack BSc (Pharm), PharmD Professor Faculty of Pharmaceutical Sciences University of British Columbia Vancouver, BC, Canada
James McCormack BSc (Pharm), PharmD Professor Faculty of Pharmaceutical Sciences University of British Columbia Vancouver, BC, Canada My Agenda Discuss the best available evidence Put the evidence into
More informationCANNABIS FOR MEDICAL PURPOSES EVIDENCE GUIDE. Information for Pharmacists and Other Health Care Professionals
CANNABIS FOR MEDICAL PURPOSES EVIDENCE GUIDE Information for Pharmacists and Other Health Care Professionals January 25, 2018 CONTENTS General Pain... 3 Acute Pain... 3 Cancer Pain... 4 Neuropathic Pain...
More informationClinical Policy Title: Strep testing
Clinical Policy Title: Strep testing Clinical Policy Number: 07.01.09 Effective Date: December 1, 2017 Initial Review Date: October 19, 2017 Most Recent Review Date: November 16, 2017 Next Review Date:
More informationClinical Policy Title: Ketamine for treatment-resistant depression
Clinical Policy Title: Ketamine for treatment-resistant depression Clinical Policy Number: 00.02.13 Effective Date: January 1, 2016 Initial Review Date: August 19, 2015 Most Recent Review Date: January
More informationClinical Policy Title: Zoster (shingles) vaccine
Clinical Policy Title: Zoster (shingles) vaccine Clinical Policy Number: 18.02.10 Effective Date: June 1, 2018 Initial Review Date: April 10, 2018 Most Recent Review Date: May 1, 2018 Next Review Date:
More informationClinical Policy Title: Cardiac rehabilitation
Clinical Policy Title: Cardiac rehabilitation Clinical Policy Number: 04.02.02 Effective Date: September 1, 2013 Initial Review Date: February 19, 2013 Most Recent Review Date: February 6, 2018 Next Review
More informationMedicinal cannabis. What is medicinal cannabis? What are cannabinoids? The endocannabinoid system
Medicinal cannabis What is medicinal cannabis? Broadly speaking, medicinal cannabis is cannabis prescribed to relieve the symptoms of a medical condition, such as epilepsy. It is important to make the
More informationClinical Policy Title: Fluorescence in situ hybridization for cervical cancer screening
Clinical Policy Title: Fluorescence in situ hybridization for cervical cancer screening Clinical Policy Number: 01.01.02 Effective Date: April 1, 2015 Initial Review Date: January 21, 2015 Most Recent
More informationPOLICY NUMBER: POL 153
Chapter: CLAIMS Subject: MEDICAL CANNABIS Effective Date: October 25, 2018 Last Update: October 25, 2018 PURPOSE STATEMENT The purpose of this policy is to explain how the Workers Compensation Board determines
More informationResearch: Medical Cannabis
Research: Medical Cannabis Background The hemp plant Cannabis sativa (cannabis) is commonly known as marijuana and can be used as a therapy to alleviate symptoms such as pain and fatigue caused by chronic
More informationMedical vs Recreational Use of Cannabis. 11 th December 2017
1 Medical vs Recreational Use of Cannabis 11 th December 2017 2 Defining Cannabis and Chemical Constituents Cannabis is a plant species. Two main Cannabis sub-species are Cannabis Sativa and Cannabis Indica.
More informationMedical Marijuana Martin P. Eason MD, JD Associate Chief of Staff for Education Mountain Home VA Medical Center. Disclosure.
Medical Marijuana Martin P. Eason MD, JD Associate Chief of Staff for Education Mountain Home VA Medical Center Controversies in Pain Management Conference Johnson City, TN November 13, 2015 Disclosure
More informationCANNABIS AND CANNABINOIDS: 2017 REPORT, U.S. NATIONAL ACADEMIES OF SCIENCES, ENGINEERING AND MEDICINE
1 CANNABIS AND CANNABINOIDS: 2017 REPORT, U.S. NATIONAL ACADEMIES OF SCIENCES, ENGINEERING AND MEDICINE The Health Effects of Cannabis and Cannabinoids. The Current State of Evidence and Recommendations
More informationMedical Marijuana. Navigating Medical Marijuana in Workers Compensation
Medical Marijuana Navigating Medical Marijuana in Workers Compensation Agenda Federal and State Laws Public Health Adverse Effects & Concerns Clinical Use Implications for Employers Implications for Workers
More informationCoalition for Medical Marijuana Research & Education
Coalition for Medical Marijuana Research & Education Nagi Kumar, Ph.D., R.D., FADA Professor, Oncologic Sciences Director, Cancer Chemoprevention Executive Director, Coalition for Medical Marijuana Research
More informationDr. Hagit Marchaim, Regulatory Affairs & Drug Development Consulting - HMC
Dr. Hagit Marchaim, Regulatory Affairs & Drug Development Consulting - HMC 1 Disclosures I (Dr. Hagit Marchaim) have no financial relationships to disclose concerning the content of this presentation or
More informationMedical Cannabis. Danial Schecter, MD, CCFP. Vocational Rehabilitation Association November 7th, Executive Director Cannabinoid Medical Clinic
Medical Cannabis Danial Schecter, MD, CCFP Executive Director Cannabinoid Medical Clinic Vocational Rehabilitation Association November 7th, 2014 Conflict of Interest This program has not received financial
More information4/15/2019. US States with Marijuana Laws in Have ACOG and SMFM taken notice? THE EFFECTS OF MARIJUANA USE ON PREGNANCY AND LACTATION
THE EFFECTS OF MARIJUANA USE ON PREGNANCY AND LACTATION Susan R Davidson, MD Maternal Fetal Medicine Department of Ob/Gyn St. Mary s Hospital Madison, WI SSM Health I HAVE NO FINANCIAL DISCLOSURES TO REPORT
More informationMEDICAL MARIJUANA: WHAT S THE EVIDENCE?
MEDICAL MARIJUANA: WHAT S THE EVIDENCE? L A U R A A. M A R K L E Y, M D B O A R D - C E R T I F I E D I N P E D I A T R I C S / G E N E R A L P S Y C H I A T R Y / C H I L D & A D O L E S C E N T P S Y
More informationDr. G. Michael (Michael) Allan EDMONTON AB Dr. Christina (Tina) S. Korownyk EDMONTON AB MEDICAL CANNABANOIDS IN PRIMARY CARE
Society of Rural Physicians of Canada 26TH ANNUAL RURAL AND REMOTE MEDICINE COURSE ST. JOHN'S NEWFOUNDLAND AND LABRADOR APRIL 12-14, 2018 262 Dr. G. Michael (Michael) Allan EDMONTON AB Dr. Christina (Tina)
More informationClinical Policy Title: Abdominal aortic aneurysm screening
Clinical Policy Title: Abdominal aortic aneurysm screening Clinical Policy Number: 08.01.10 Effective Date: August 1, 2017 Initial Review Date: June 22, 2017 Most Recent Review Date: June 5, 2018 Next
More informationThe Sale of Cannabis in Pharmacies. Michael H. Ghobrial, PharmD, JD Associate Director, Health Policy American Pharmacists Association
The Sale of Cannabis in Pharmacies Michael H. Ghobrial, PharmD, JD Associate Director, Health Policy American Pharmacists Association Development This activity was developed by the American Pharmacists
More informationBudding Therapies: Medical Cannabis and its Uses
Budding Therapies: Medical Cannabis and its Uses MARIAH CADAVOS, PHARMD & VIVIAN NGUYEN, PHARMD PGY1 PHARMACY PRACTICE RESIDENTS FEBRUARY 10, 2019 1 Disclosures & Disclaimer Both presenters have nothing
More informationFederal Law: Marijuana
Federal Law: Marijuana Marijuana is a Schedule I drug under Federal Controlled Substances Act Makes possession, usage, purchase, sale, and/or cultivation of marijuana illegal at the federal level May not
More informationClinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden
Clinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden Clinical Policy Number: 05.01.03 Effective Date: January 1, 2016 Initial Review Date: July 15, 2015 Most Recent Review Date:
More informationClinical Policy Title: Genicular nerve block
Clinical Policy Title: Genicular nerve block Clinical Policy Number: 14.01.10 Effective Date: October 1, 2017 Initial Review Date: September 21, 2017 Most Recent Review Date: October 19, 2017 Next Review
More informationUSING ALTERNATIVE MEDICATION: MEDICAL CANNABIS (MARIJUANA)--BENEFITS AND HARMFUL EFFECTS JENNIFER KAPUR, PHARM.D. MARCH 1, 2016
USING ALTERNATIVE MEDICATION: MEDICAL CANNABIS (MARIJUANA)--BENEFITS AND HARMFUL EFFECTS JENNIFER KAPUR, PHARM.D. MARCH 1, 2016 OBJECTIVES Compare and contrast federal law and state laws regarding marijuana
More informationCannabis and What we Know. Bonnie Schnittker RN PHN Public Health Nurse October 20, 2017
Cannabis and What we Know Bonnie Schnittker RN PHN Public Health Nurse October 20, 2017 We All Have a Role to Play! Objectives What is Cannabis? What do we know about the health effects? Legalization:
More informationMedical Marijuana: The Move to Schedule II
Medical Marijuana: The Move to Schedule II David Deitz, MD, PhD David Deitz & Associates Today s discussion Does medical marijuana actually treat anything? What are the workplace issues? What are the interactions
More informationClinical Policy Title: Abdominal aortic aneurysm screening
Clinical Policy Title: Abdominal aortic aneurysm screening Clinical Policy Number: 08.01.10 Effective Date: August 1, 2017 Initial Review Date: June 22, 2017 Most Recent Review Date: June 5, 2018 Next
More informationCannabinoids: access and symptom management in cancer
Cannabinoids: access and symptom management in cancer Appetite stimulation Anecdotal reports suggest marijuana stimulates appetite AIDS/HIV dronabinol 2.5 mg bd v placebo (n=88) increase in appetite 38%
More informationClinical Policy Title: Abdominal aortic aneurysm screening
Clinical Policy Title: Abdominal aortic aneurysm screening Clinical Policy Number: 08.01.10 Effective Date: August 1, 2017 Initial Review Date: June 22, 2017 Most Recent Review Date: July 20, 2017 Next
More informationChanging the Drug Enforcement Administration (DEA) Schedule of Tetrahydrocannabinol (THC), Cannabidiol and Combinations to Promote Research
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 TITLE: Changing the Drug Enforcement Administration (DEA) Schedule of Tetrahydrocannabinol
More informationExplanatory note for Operational Policy Manual (OPM) # , Cannabis for Medical Purposes
Medical Cannabis Explanatory note for Operational Policy Manual (OPM) #17-01-10, Cannabis for Medical Purposes WSIB Explanatory note for OPM #17-01-10, Cannabis for Medical Purposes January 2019 1 Table
More informationClinical Policy Title: Altered auditory feedback devices for speech dysfluency (stuttering)
Clinical Policy Title: Altered auditory feedback devices for speech dysfluency (stuttering) Clinical Policy Number: 17.02.02 Effective Date: January 1, 2016 Initial Review Date: August 19, 2015 Most Recent
More informationCDHA 2016 Fall Symposium. Speaker Handout Files. For registered attendees only
CDHA 2016 Fall Symposium Speaker Handout Files For registered attendees only Providing Care in a Marijuana Legal World Heather Rogers, BSDH heatherrdh@heatherrdh.com Objectives We will discuss some of
More informationThe Effects known & unknown of Marijuana in Older Adults. Danielle Fixen, PharmD, BCGP, BCPS University of Colorado School of Pharmacy
The Effects known & unknown of Marijuana in Older Adults Danielle Fixen, PharmD, BCGP, BCPS University of Colorado School of Pharmacy Learning Objectives 1. Review various dosing strategies for medical
More information9/28/2015. Support. R01CA A1 Intervening with smoking parents of inpatients to reduce
Medical marijuana and the impact of marijuana policy on children Karen M. Wilson, MD, MPH, FAAP Associate Professor of Pediatrics Section Head, Pediatric Hospital Medicine University of Colorado School
More informationThe Highs and Lows of Medical Marijuana
The Highs and Lows of Medical Marijuana Jill Vargo Cavalet, MHS, PA-C Marijuana use is prevalent worldwide yet remains controversial in health care. The general public often regards marijuana as a benign
More informationThe Return of Medicinal Cannabis
The Return of Medicinal Cannabis George Kolodner, M.D. DLFAPA FASAM Chief Clinical Officer Clinical Professor of Psychiatry Georgetown University School of Medicine University of Maryland School of Medicine
More informationOutcome. Educating Ohio Providers On The Basics Related To Recommending Medical Marijuana. Connie J. Cerilli, APRN, FNP-C
Educating Ohio Providers On The Basics Related To Recommending Medical Marijuana Connie J. Cerilli, APRN, FNP-C Outcome Participants will be able to list 3 approved medical conditions Participants will
More informationEducating Ohio Providers On The Basics Related To Recommending Medical Marijuana. Connie J. Cerilli, APRN, FNP-C
Educating Ohio Providers On The Basics Related To Recommending Medical Marijuana Connie J. Cerilli, APRN, FNP-C Outcome Participants will be able to list 3 approved medical conditions Participants will
More informationObjectives. 1. Review controversy 2. Pathophysiology 3. Indications for Use 4. Adverse Effects 5. How Patients Access
Medical Marijuana Deb Evans, RN, MScN, CON(C), CHPCN(C) Clinical Nurse Specialist Pain and Symptom Management Team Juravinski Cancer Centre May 29, 2014 Objectives 1. Review controversy 2. Pathophysiology
More informationClinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden
Clinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden Clinical Policy Number: 05.01.03 Effective Date: January 1, 2016 Initial Review Date: July 15, 2015 Most Recent Review Date:
More informationWHO Expert Committee on Drug Dependence Pre-Review: Extracts and tinctures of cannabis. Expert Peer Review 2
WHO Expert Committee on Drug Dependence Pre-Review: Extracts and tinctures of cannabis Expert Peer Review 2 1. Comments based on the review report a. Evidence on dependence and abuse potential Extracts
More informationThis questionnaire will ask you about approved medical use of extracts and tinctures of cannabis at national level.
Introduction This questionnaire will ask you about approved medical use of extracts and tinctures of cannabis at national level. Definition: The term "extracts and tinctures" refers to substances that
More informationCANNABIS FOR THE RHEUMATOLOGIST
CANNABIS FOR THE RHEUMATOLOGIST Dr Jagtar Singh Nijjar NIHR Clinical Lecturer in Rheumatology Disclosures None 1 Overview The history of cannabis use Anecdotal use of cannabis in chronic pain The biology
More informationMEDICAL CANNABIS IN MINNESOTA
MEDICAL CANNABIS IN MINNESOTA MINNESOTA ACADEMY OF PHYSICIAN ASSISTANTS MARCH 18, 2016 TOM ARNESON, MD, MPH MDH OFFICE OF MEDICAL CANNABIS 2014: Minnesota becomes 22 nd state with a medical cannabis program
More informationThe products being taken by children with epilepsy are not the equivalent of the marijuana widely used for recreational purposes.
Epilepsy Foundation of Colorado The Use of Cannabis to Treat Children with Epilepsy Updated February 2016 The use of extracts from marijuana plants (cannabis) to treat children with epilepsy has been in
More informationResearch on Cannabis and PD: Is there any evidence?
Research on Cannabis and PD: Is there any evidence? Benzi M. Kluger, MD, MS Associate Professor of Neurology and Psychiatry Director Movement Disorders Center University of Colorado Denver DISCLOSURES
More informationWHO Expert Committee on Drug Dependence Pre-Review: Cannabis plant and resin. Expert Peer Review 2
WHO Expert Committee on Drug Dependence Pre-Review: Cannabis plant and resin Expert Peer Review 2 1. Comments based on the review report a. Evidence on dependence and abuse potential Dependence potential:
More informationCannabis and cannabinoids for medicinal purposes
Cannabis and cannabinoids for medicinal purposes International Evidence and Evidence for Practice in Australia Michael Farrell Louisa Degenhardt, Wayne Hall, Nicholas Buckley, Megan Weir, Suzi Neilsen,
More informationCannabis Use Disorder: What Nurses Need to Know. Bari K Platter, MS, RN, PMHCNS-BC Clinical Nurse Specialist
Cannabis Use Disorder: What Nurses Need to Know Bari K Platter, MS, RN, PMHCNS-BC Clinical Nurse Specialist MARIJUANA POTENCY Average THC and CBD Levels in the U.S. 1960-2011 14 12 10 8 6 4 THC: Psychoactive
More information5/31/2017 CANNABIS, CANNBINOIDS, AND MEDICINE: WHAT DOES THE EVIDENCE TELL US? DISCLOSURE STATEMENT OBJECTIVES
CANNABIS, CANNBINOIDS, AND MEDICINE: WHAT DOES THE EVIDENCE TELL US? David Galbis-Reig, M.D., DFASAM Medical Director of Addiction Services Ascension Wisconsin All Saints Racine, Wisconsin 53043 DISCLOSURE
More informationQuestionnaire 1 of 5: Cannabis Plant and Cannabis Resin. Introduction
Introduction This is one of five questionnaires that Member States are invited to complete ahead of the 40th WHO Expert Committee on Drug Dependence. This questionnaire will ask you about cannabis plant
More informationINTRODUCTION WHAT IS MARIJUANA 2/28/2018
INTRODUCTION AT THE END OF THE SESSION, YOU WILL ASSESS THE USE AND IMPACT (SIDE EFFECTS) OF MARIJUANA ON PATIENTS EXPLORE CANNABIS THERAPY LEGALITY AND PRACTICALITY POSSESS STRATEGIES TO PROVIDE PSYCHO-EDUCATIONAL
More informationMedical Cannabis and OMT
Medical Cannabis and OMT David R. Beatty, DO Professor of Osteopathic Principles and Practice, WVSOM November 4, 2017 Objectives At the completion of this presentation the attendee should be able to: 1.
More informationMedical Marijuana Update Chris Belletieri, DO
Dr. Belletieri has provided no disclosures. Graduated PCOM in 1996 In private practice since 1999 Board Certified in FP since 1999 Program Director of FP residency at Lower Bucks Hospital in Bristol, PA
More informationCannabis Use: Scope of the Issue
Three Areas of Focus How Changing Cannabis Policy Will Affect Your Practice Kevin P. Hill, MD, MHS Director, McLean Hospital Division of Alcohol and Drug Abuse Belmont, MA Assistant Professor of Psychiatry,
More information9/13/2017. Marijuana and the Brain Matthew Wong, MD Assistant Professor, Department of Neurology, Epilepsy Section. Disclosures.
Marijuana and the Brain Matthew Wong, MD Assistant Professor, Department of Neurology, Epilepsy Section Disclosures Site principal investigator of studies of cannabidiol(epidiolex) in the treatment of
More informationMarijuana. DATE: February 21, 2017 PRESENTED BY: Melissa Weimer, DO, Assistant Professor of Medicine
Marijuana DATE: February 21, 2017 PRESENTED BY: Melissa Weimer, DO, Assistant Professor of Medicine Objectives Describe marijuana laws in the state of Oregon and the nation List evidence available for
More informationMarijuana as Medicine
Marijuana as Medicine What is medical marijuana? The term medical marijuana refers to using the whole, unprocessed marijuana plant or its basic extracts to treat symptoms of illness and other conditions.
More information8/31/2016. Workplace Implications of Marijuana in the US. Goal
Workplace Implications of Marijuana in the US Copyright 420 Medicated.com Goal Inform and provoke discussion about the future for patients, staff and employers in regard to this rapidly evolving and important
More informationThis is a duplicated text of a letter from GW Pharma Ltd. Contact the company for a copy of any references, attachments or enclosures.
Health Canada posts safety alerts, public health advisories, press releases and other notices from industry as a service to health professionals, consumers and other interested parties. Although Health
More informationDoc, will you sign my medical. Fellow in Hematology/Medical Oncology General Internal Medicine Grand Rounds
Doc, will you sign my medical marijuana card? Daniel W. Bowles, MD Fellow in Hematology/Medical Oncology General Internal Medicine i Grand Rounds September 21, 2010 Disclosures Skeptical about marijuana
More informationCurious about Cannabis? Navigating the cannabis landscape in Pennsylvania LINDSEY MESTON, PHARMD ASHLEY FIRM, PHARMD
Curious about Cannabis? Navigating the cannabis landscape in Pennsylvania LINDSEY MESTON, PHARMD ASHLEY FIRM, PHARMD Speaker Disclosures We have/had no financial relationships with any commercial interests
More informationMedical Marijuana. Speaker Disclosure Requirements. Share with a Partner 4/10/2015
Medical Marijuana Kent W. Peterson, MD, FACOEM Occupational Health Strategies, Inc. Charlottesville, VA Speaker Disclosure Requirements 1. Do not dispense, prescribe, refer or recommend MMJ 2. Have no
More informationGuidance for the use of. medicinal cannabis. in Australia. Patient information
Guidance for the use of medicinal cannabis in Australia Patient information Version 1, December 2017 Copyright Commonwealth of Australia 2017 This work is copyright. You may reproduce the whole or part
More informationCannabis and Cannabinoids: Review of Existing and Potential Therapeutic Applications in Oncology
Cannabis and Cannabinoids: Review of Existing and Potential Therapeutic Applications in Oncology 2 Pamela C. Cartright, MAE, RT (R)(T) Assistant Professor and Program Director Radiation Therapy Program
More informationMedicinal Cannabis Dosage Forms in California
Mica Gross President Sante Botanica / COO MDBioLogics Medicinal Cannabis Dosage Forms in California An Overview of Cannabis Dosage Forms Forms of dosage are the specific vehicles by which cannabis, or
More informationCannabidiol as a potential treatment for anxiety disorders. Esther Blessing, MD PhD
Cannabidiol as a potential treatment for anxiety disorders Esther Blessing, MD PhD Overview History and of cannabidiol (CBD) and cannabis Safety and tolerability of CBD CBD pharmacology Clinical need for
More informationDr. Meldon Kahan. Women s College Hospital. with PIA LAW
with PIA LAW and Toronto ABI Network Dr. Meldon Kahan Women s College Hospital Dr. Meldon Kahan is an Associate Professor in the Department of Family Medicine at University of Toronto, and Medical Director
More informationMedicinal Cannabis. Patient Log Book. Record your cannabis use and find the right dose
Medicinal Cannabis Patient Log Book Record your cannabis use and find the right dose 1 Introduction A federal system is in place for medicinal cannabis that is distinct from recreational sales. To get
More informationMedical Marihuana for Patients in the Lymphoma Setting. Speakers: Ruth Turner, RN, Con Rob Laister, PhD
Medical Marihuana for Patients in the Lymphoma Setting Speakers: Ruth Turner, RN, Con Rob Laister, PhD Medical Marihuana for Patients in the Lymhoma Setting Disclosure: No endorsement or promotion of marihuana
More informationIs the most common illicit drug used in the United States. After a period of decline in the last decade, its use has been increasing among young
The Facts Cannabis, commonly known as marijuana and by numerous other names, is a preparation of the cannabis plant intended for use as a psychoactive drug and now as medicine. Marijuana also refers to
More informationDear Colleague SUPPLEMENTARY INFORMATION ON CANNABIS BASED PRODUCTS FOR MEDICINAL USE
Directorate of Chief Medical Officer T: 0131-244 2470 E: John.Hannah@gov.scot Dear Colleague SUPPLEMENTARY INFORMATION ON CANNABIS BASED PRODUCTS FOR MEDICINAL USE Following my letter of 31 October 2018
More informationMEDICAL CANNABIS IN MINNESOTA
MEDICAL CANNABIS IN MINNESOTA EPILEPSY & SEIZURES WELLNESS EXPO APRIL 16, 2016 MICHELLE LARSON, MPA MDH OFFICE OF MEDICAL CANNABIS 2014: Minnesota becomes 22 nd state with a medical cannabis program State
More informationHEALTH WELLNESS COMMUNITY
HEALTH WELLNESS COMMUNITY As with all modern medicines, our understanding of cannabis and its benefits has deepened over time thanks to groundbreaking advancements in research and technology. At Trilogy
More informationMinnesota. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile Minnesota Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points
More informationSECTION V: EMPLOYEES POLICY 5375 MEDICAL MARIJUANA, HEMP & CANNABIDIOL (CBD)
Regardless of a student, employee, parent or any individual s status as a medical marijuana license holder, marijuana is not allowed on the premises of the district or in any school vehicle or in any personal
More informationIs there a role for medical marijuana in the management of IBD? Jami A. Kinnucan, MD Division of Gastroenterology University of Michigan Hospital
Is there a role for medical marijuana in the management of IBD? Jami A. Kinnucan, MD Division of Gastroenterology University of Michigan Hospital Disclosures No relevant financial or relationship disclosures
More informationClinical Policy Title: Measurement of serum antibodies to infliximab and adalimumab
Clinical Policy Title: Measurement of serum antibodies to infliximab and adalimumab Clinical Policy Number: 01.01.03 Effective Date: January 1, 2016 Initial Review Date: September 16, 2015 Most Recent
More information